Lilly 4Q Results

Lilly

4Q Revenues: $13.5 billion (45%)

4Q Earnings: $4.4 billion (+101%)

FY Revenues: $45.0 billion (32%)

FY Earnings: $10.6 billion (+102%)

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh and Zepbound, grew by $3.15 billion to $5.64 billion, led by Zepbound and Mounjaro.

Growth Products revenue, which consists of Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio, increased 13% to $5.95 billion, driven by Verzenio and Jardiance, partially offset by lower Trulicity sales. Verzenio sales were $1.56 billion, up 36%. Jardiance sales were up 50% to $1.2 billion. Trulicity sales were down 25% to $1.25 billion.

In the quarter, the FDA approved of Zepbound for a new indication as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity.